Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'
Nomura believes the company's strong Q2FY27 performance, particularly the continued momentum in the US market, supports its growth outlook. It also sees scope for an expansion in the stock's valuation multiple,…
